BioSpace News Archive

RosVivo Therapeutics, Inc. announced that it has signed a Material Transfer Agreement with one of the largest global pharmaceutical companies Eli Lilly and Company for commercial development of diabetes and obesity treatments.

Eyebiotech Limited, a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, announced the completion of a successful $65 million Series A funding round.

AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing topical biologic therapies for systemic inflammatory conditions, announced positive pivotal Phase 2b results from its trial evaluating B244 in both pruritus and appearance of atopic dermatitis.

Theravance Biopharma, Inc. will participate in the Respiratory/Infections Corporate Panel Discussion at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, at 2:10 pm ET.

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced that its Chief Executive Officer was named in The Healthcare Technology Report’s list of Top 25 Biotech CEOs of 2022.

BioCryst Pharmaceuticals, Inc. today announced the enrollment of the first patient in the RENEW proof-of-concept basket study with its oral Factor D inhibitor, BCX9930, in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).

Microbix Biosystems Inc. announces that Ms. Jennifer Stewart, an accomplished leader in Canadian business, government, and public affairs, has been nominated to become a member of its Board of Directors.

Chimerix today announced that it will host a live conference call and audio webcast on Tuesday, March 1, 2022 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2021, and to provide a business overview.

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the peer-reviewed publication of data from a Phase 1 clinical trial of fosgonimeton (ATH-1017) in The Journal of Alzheimer’s Disease.

Albireo Pharma, Inc. announced that the National Institute for Health and Care Excellence has issued guidance that recommends Bylvay for the treatment of all types of progressive familial intrahepatic cholestasis in people aged six months and older.